PATENT CLAIM ANALYSIS

Application Number: 16219589
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "210180"]

Abstract:
The subject matter generally relates to methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.

Claim (Index 6):
A method of  claim 1 , wherein the PDE1 inhibitor is compound of Formula V: wherein\n (i) R 1  is H or C 1-4  alkyl (e.g., methyl); \n (ii) R 4  is H or C 1-4  alkyl and R 2  and R 3  are, independently, H or C 1-4  alkyl (e.g., R 2  and R 3  are both methyl, or R 2  is H and R 3  is isopropyl), aryl, heteroaryl, (optionally hetero)arylalkoxy, or (optionally hetero)arylalkyl; \n or \n R 2  is H and R 3  and R 4  together form a di-, tri- or tetramethylene bridge (pref. wherein the R 3  and R 4  together have the cis configuration, e.g., where the carbons carrying R 3  and R 4  have the R and S configurations, respectively); \n (iii) R 5  is a substituted heteroarylalkyl, e.g., substituted with haloalkyl \n or \n R 5  is attached to one of the nitrogens on the pyrazolo portion of Formula V and is a moiety of Formula A \n wherein X, Y and Z are, independently, N or C, and R 8 , R 9 , R 11  and R 12  are independently H or halogen (e.g., Cl or F), and R 10  is halogen, alkyl, cycloalkyl, haloalkyl (e.g., trifluoromethyl), aryl (e.g., phenyl), heteroaryl (e.g., pyridyl (for example pyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl)), diazolyl, triazolyl, tetrazolyl, arylcarbonyl (e.g., benzoyl), alkylsulfonyl (e.g., methylsulfonyl), heteroarylcarbonyl, or alkoxycarbonyl; provided that when X, Y, or Z is nitrogen, R 8 , R 9 , or R 10 , respectively, is not present; and (iv) R 6  is H, alkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), arylamino (e.g., phenylamino), heteroarylamino, N,N-dialkylamino, N,N-diarylamino, or N-aryl-N-(arylakyl)amino (e.g., N-phenyl-N-(1,1\u2032-biphen-4-ylmethyl)amino); and (v) n=0 or 1; (vi) when n=1, A is \u2014C(R 13 R 14 )\u2014\n wherein R 13  and R 14 , are, independently, H or C 1-4  alkyl, aryl, heteroaryl, (optionally hetero)arylalkoxy or (optionally hetero)arylalkyl; \n wherein aryl is optionally substituted with C 1-4  alkyl, halogen, haloC 1-4 alkyl, hydroxyl or C 1-4 carboxy or an additional aryl or heteroaryl; or heteroaryl or thiadiazolyl is optionally substituted with C 1-4 alkyl, halogen, haloC 1-4 alkyl, hydroxyl or C 1-4 carboxy; in free or pharmaceutically acceptable salt form.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 98.0
- Lexical Diversity: 1.54545
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14777448', '15406346', '14767489', '15709258', '14820323']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7841038524254301
- 35 USC 102 Novelty (BERT): 0.548374637623568
- Combined Prediction Score: 0.7605309309452439
- Mean Citation Score: 348.187806
- Max Citation Score: 492.94012
- Similarity Product: 353.4707126703858

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test